Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04305236
Recruitment Status : Recruiting
First Posted : March 12, 2020
Last Update Posted : January 20, 2021
Eli Lilly and Company
Information provided by (Responsible Party):
Ritesh Parajuli, University of California, Irvine

Brief Summary:
This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance.

Condition or disease Intervention/treatment Phase
Breast Neoplasm Hormone Receptor Positive Breast Carcinoma Drug: Abemaciclib Drug: Fulvestrant Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open Label Trial of Neo-Adjuvant Abemaciclib With Fulvestrant in Patients Who Develop Localized Recurrence While on Adjuvant Endocrine Therapy With Molecular Evidence of Endocrine Resistance
Actual Study Start Date : July 23, 2020
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Abemaciclib and Fulvestrant
Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
Drug: Abemaciclib
Given PO
Other Name: VERZENIO™

Drug: Fulvestrant
Given Intramuscularly
Other Name: FASLODEX®

Primary Outcome Measures :
  1. Percentage of Participants with a pathological complete response [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    This is defined as the percentage of subjects who achieve a pathological complete response (pCR). A pCR is defined by no evidence of tumor cells in the final surgical specimen.

Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    To assess the overall response rate to the combination of Abemaciclib and Fulvestrant. Overall response rate (ORR) is defined as confirmed complete response (CR) and partial response (PR). Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1): Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as a 30% decrease in the sum of diameters of target lesions. ORR = CR + PR

  2. Percentage of Participants who undergo breast conserving surgery [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    This is defined as the percentage of subjects who undergo breast conserving surgery after receiving Abemaciclib and Fulvestrant

  3. Recurrence Disease Free Survival [ Time Frame: Up to 5 years ]
    Recurrence disease free survival will be defined as the time from surgery until patient develops recurrence.

  4. Percentage of Grade 3-5 Adverse Events [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    To evaluate the safety and tolerability of administering Abemaciclib and Fulvestrant. Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0.

  5. Percentage change in Ki 67 [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    Percentage change in the Ki 67 will be evaluated from baseline to the treated specimen after breast surgery

  6. Preoperative Endocrine Prognostic Index Score [ Time Frame: From start of study treatment to surgery, on average we expect 6 months. ]
    The preoperative endocrine prognostic index (PEPI) Score is a score that is used in clinical trials to assess response to Neo-Adjuvant endocrine therapy. The PEPI score takes into account the tumor and nodal stage, level of ER expression and Ki 67 following neoadjuvant endocrine therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a diagnosis of HR+ breast cancer. To fulfill the requirement of HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (ER, progesterone receptor [PgR]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010):

    1. For ER and PgR assays to be considered positive, ≥1% of tumor cell nuclei must be immunoreactive by immunohistochemistry (IHC) (Hammond et al. 2010).

  • Patients must have Loco regional breast cancer (Stage I, Stage II and stage III per AJCC 8th edition criteria for staging of breast cancer)
  • Patients must have localized recurrence while on adjuvant endocrine therapy
  • Patients must have any known molecular evidence of endocrine resistance by next generation sequencing
  • Age ≥ 18 years.
  • ECOG performance status 0-1
  • Have post-menopausal status as defined by following:

    1. Prior bilateral oophorectomy
    2. Age ≥ 60 years
    3. Age < 60 and amenorrheic (non-treatment-induced amenorrhea secondary to tamoxifen, toremifene, ovarian suppression, or chemotherapy) for at least 12 months. Follicle-stimulating hormone (FSH) and estradiol must be in the postmenopausal range.
  • Have at least one measurable disease as defined per RECIST 1.1
  • Adequate organ and marrow function as defined below:

    1. Hemoglobin* > 8 g/dL
    2. Absolute neutrophil count ≥ 1,500/mcL
    3. Total bilirubin ≤ 1.5 X institutional ULN, Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted
    4. AST (SGOT)/ALT (SPGT) ≤ 2.5 X institutional ULN
    5. Creatinine ≤ 1.5 X institutional ULN

      1. *Patients may receive transfusion of packed red blood cells (PRBC) to achieve this hemoglobin level at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after the PRBC transfusion.
  • Able to swallow oral medications
  • Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and screening for the study.
  • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to enrollment. A washout period of at least 21 days is required between last chemotherapy dose and enrollment (provided the patient did not receive radiotherapy).
  • Any known markers of response or resistance to CDK 4/6 inhibitors to be present in the biopsy specimen
  • If patients have been treated with prior Neo-Adjuvant chemotherapy at the time of primary diagnosis and not at the time of recurrence, they will be included in the study.
  • Must be able to sign a written informed consent, are reliable, willing to be available for the duration of the study and are willing to follow study procedures

Exclusion Criteria:

  • Stage IV metastatic breast cancer

    1. This study will utilize the American Joint Committee on Cancer (AJCC) staging system, eight edition that provides a strategy for grouping patients with respect to prognosis. The AJCC has designated staging by TNM classification. The researchers will also review tumor size, lymph node status, and estrogen-receptor and progesterone-receptor levels in the tumor tissue.

  • Patients with HER2 positive and triple negative breast cancer

    1. To fulfill the requirement of HER2- and Triple negative disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 or should not express ER or PR receptors by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP guidelines (Wolff et al. 2013).

  • Inflammatory breast cancer
  • Newly diagnosed endocrine naïve patients
  • No molecular evidence of endocrine resistance
  • Prior treatment with any CDK 4/6 inhibitor and/or Fulvestrant
  • Pre-menopausal women
  • Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study. If a patient is currently enrolled in a clinical trial involving non-approved use of a device, then agreement with the principal investigator is required to establish eligibility
  • Have had major surgery within 14 days prior to enrollment to allow for post-operative healing of the surgical wound
  • Have initiated bisphosphonates or approved RANK ligand therapy for breast cancer with osseous metastasis, if patients are received Zolendronic acid or Denosumab in the adjuvant manner then such patients will be allowed participate
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel or preexisting Crohn's disease or ulcerative colitis , interstitial lung disease, severe dyspnea at rest, any pre-existing chronic condition resulting in baseline grade 2 or higher diarrhea)
  • Have a personal history of any of the following conditions: syncope or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation or sudden cardiac arrest
  • Have a history of any other cancer (except for non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission with no therapy for a minimum of three years or have received an autologous or allogeneic stem-cell transplant
  • Have an active bacterial or fungal infection or a detectable viral infection (for example HIV or viral hepatitis). Screening is not required for enrollment
  • Recent therapy with a biologic agent or a monoclonal therapy is excluded. Wash out of at least three half-lives of monoclonal antibody would be required to be enrolled.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04305236

Layout table for location contacts
Contact: Chao Family Comprehensive Cancer Center University of California, Irvine 1-877-827-7883
Contact: University of California Irvine Medical

Layout table for location information
United States, California
Chao Family Comprehensive Cancer Center, University of California, Irvine Recruiting
Orange, California, United States, 92868
Contact: Ritesh Parajuli, MD    877-827-8839   
Sponsors and Collaborators
University of California, Irvine
Eli Lilly and Company
Layout table for investigator information
Principal Investigator: Ritesh Parajuli, MD Chao Family Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Ritesh Parajuli, Assistant Clinical Professor, University of California, Irvine Identifier: NCT04305236    
Other Study ID Numbers: UCI 18-79 [HS# 2020-5660]
2020-5660 ( Other Identifier: University of California, Irvine )
First Posted: March 12, 2020    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs